Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831506 · ClinicalTrials.gov registry record · Phase 1
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00831506 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT00831506, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.
Interventions
- DRUG digoxin
- DRUG dimebon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831506
The ClinicalTrials.gov registry entry for NCT00831506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which digoxin is the first listed.
NCT00831506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831506 about?
NCT00831506 is a clinical study titled "Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects". This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended ...
What is the current status of trial NCT00831506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-02. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00831506?
The interventions under investigation include: digoxin (DRUG), dimebon (DRUG).
Who is sponsoring clinical trial NCT00831506?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.